Tactile Systems Technology EV/EBIT TCMD
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2017.
- Today, Oct 23, 2026
- 13.3×
- 9-year median
- 96.6×
- Against its 9-year history
- 16th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 8.0× to 431×
- Peer median
- 22.8×
Tactile Systems Technology's EV/EBIT is 13.3× as of Oct 23, 2026.
That is below its 9-year median of 96.6×, lower than on 84% of days in the last 9 years.
Over that time it ranged from 8.0× in May 2025 to 431× in Nov 2021.
The median for 10 medical instruments and supplies stocks of a similar size is 22.8×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 13.3× | 12.1× | 26.7× |
| 2025 | 25.9× | 8.0× | 25.9× |
| 2024 | 16.1× | 11.1× | 25.4× |
| 2023 | 23.0× | 17.0× | 96.3× |
| 2022 | 233× | 233× | 275× |
| 2021 | 289× | 133× | 431× |
| 2020 | 96.8× | 53.8× | 144× |
| 2019 | 141× | 106× | 239× |
| 2018 | 132× | 127× | 224× |
| 2017 | 201× | 113× | 285× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Tactile Systems Technology's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| TCMDTactile Systems Technology | 13.3× |
| MDXGMimedx | 51.6× |
| MOVMovado | 11.8× |
| EMBCEmbecta | 6.7× |
| INFUInfuSystem | 22.4× |
| IRMDIradimed | 37.7× |
| STAAStaar Surgical | 57.7× |
| UTMDUtah Medical Products | 6.0× |
| BVSBioventus | 26.2× |
| CDRECadre | 23.2× |
| PDEXPro DEX | 16.0× |
| Peer median | 22.8× |
Where Tactile Systems Technology ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Tactile Systems Technology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.